{"schema":"sb.node.v1","id":"sb:e/16376562929e1bbae6b0e61a","kind":"entity","label":{"text":"egfr-mutated","locale":"en"},"identity":{"anchor":"label:en:egfr-mutated","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-09T19:01:08.010113+00:00","snapshot":"deploy 7349c4313af420e6d6fc835598564cbb1892cffd"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":25,"separatePublishers":8,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim"},"admission":{"state":"canonical","reason":"entity graph provenance 'curated'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-09-03","to":"2026-10-05","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.36: about 64% of mentions carry no typed assertion"]}},"dimensions":{"domains":["society_news","fda_decisions","precision_medicine"],"activeDays":16,"assertions":{"regulatory-approval":4,"meeting-visit":3,"election":1,"acquisition":1}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":12,"byKind":{"observation":12},"items":[{"id":"sb:o/ccae0c51fc762242acabd0a0","kind":"observation","label":"The ASCO Post · 2026-09-18 · Metastatic EGFR-Mutated NSCLC Global Study of Izalontamab Brenitecan","url":"https://ascopost.com/videos/iaslc-wclc-2026/metastatic-egfr-mutated-nsclc-global-study-of-izalontamab-brenitecan/"},{"id":"sb:o/2e395b29aca2292f4d0d4421","kind":"observation","label":"The ASCO Post · 2026-09-16 · Long-Term Benefit Seen With Adjuvant Osimertinib in EGFR-Mutated NSCLC","url":"https://ascopost.com/news/september-2026/long-term-benefit-seen-with-adjuvant-osimertinib-in-egfr-mutated-nsclc/"},{"id":"sb:o/2962c8f9e654dcd096527099","kind":"observation","label":"PR Newswire · 2026-09-12 · SystImmune, Inc. to Present New Global Data on Iza-bren (izalontamab brengitecan) in EGFR-mutated Non-Small Cell Lung Cancer at WCLC Congress 2026","url":"https://www.prnewswire.com/news-releases/systimmune-inc-to-present-new-global-data-on-iza-bren-izalontamab-brengitecan-in-egfr-mutated-non-small-cell-lung-cancer-at-wclc-congress-2026-302875960.html"},{"id":"sb:o/cc6e4750cc495c9cf9a0e942","kind":"observation","label":"The ASCO Post · 2026-10-05 · Relapsed or Refractory SCLC Phase I Study of Novel CAR T-Cell Therapy","url":"https://ascopost.com/videos/iaslc-wclc-2026/relapsed-or-refractory-sclc-phase-i-study-of-novel-car-t-cell-therapy/"},{"id":"sb:o/e734daadfcc0da8e4ceb739f","kind":"observation","label":"The ASCO Post · 2026-10-05 · Metastatic PD-L1–High NSCLC Sacituzumab Govitecan/Pembrolizumab","url":"https://ascopost.com/videos/iaslc-wclc-2026/metastatic-pd-l1-high-nsclc-sacituzumab-govitecanpembrolizumab/"},{"id":"sb:o/eb86097d896d3fbaef88184c","kind":"observation","label":"AllSci News · 2026-10-02 · AstraZeneca, Daiichi team with Summit to pair Datroway with ivonescimab in Phase III TNBC push","url":"https://allsci.com/news/biotech/datroway-ivonescimab-astrazeneca-and-daiichi/"},{"id":"sb:o/901df94790a9c91573864ae0","kind":"observation","label":"The ASCO Post · 2026-10-02 · Advanced Lung Cancer Pumitamig Plus Elfetabart Drozuntecan","url":"https://ascopost.com/videos/iaslc-wclc-2026/advanced-lung-cancer-pumitamig-plus-elfetabart-drozuntecan/"},{"id":"sb:o/e7f192ca5c1a7ae7fcc55b5d","kind":"observation","label":"The ASCO Post · 2026-09-30 · Targeting B7-H3 in Second-Line SCLC Treatment Novel ADCs","url":"https://ascopost.com/videos/iaslc-wclc-2026/targeting-b7-h3-in-second-line-sclc-treatment-novel-adcs/"},{"id":"sb:o/afefb7b3bc5e4f361a95f937","kind":"observation","label":"Fierce Pharma · 2026-09-30 · Hansoh’s Tagrisso rival loses EU approval after AstraZeneca legal challenge","url":"https://www.fiercepharma.com/pharma/hansoh-tagrisso-rival-loses-eu-approval-after-astrazeneca-legal-challenge"},{"id":"sb:o/f4315f164534eb52402506b7","kind":"observation","label":"AllSci News · 2026-09-30 · AstraZeneca seeks FDA approval for HutchMed's Orpathys plus Tagrisso in MET-driven lung cancer","url":"https://allsci.com/news/biotech/savolitinib-fda-approval-astrazeneca-seeks-for/"}],"cursor":"c1.eyJpZCI6InNiOmUvMTYzNzY1NjI5MjllMWJiYWU2YjBlNjFhIiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTA5VDE5OjAxOjA4LjAxMDExMyswMDowMCJ9","order":"newest first; we keep the 12 newest receipts for this entity. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":10,"byKind":{"co-mentioned":10},"items":[{"kind":"relation","label":"co-mentioned with egfr (25 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/d35735e0da9214b223606828"},{"kind":"relation","label":"co-mentioned with lung cancer (25 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/15e4d7b21fa9d4ff1be48cdd"},{"kind":"relation","label":"co-mentioned with her2 (14 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/2c33deb1bc83bb5dca90a3af"},{"kind":"relation","label":"co-mentioned with her2-directed (12 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/8f9242c1bdae53ce4c3b5e97"},{"kind":"relation","label":"co-mentioned with iaslc (12 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/278fcab99990589ccb198e47"},{"kind":"relation","label":"co-mentioned with immunotherapy (12 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/3031d93accd1eb3a7afa70ec"},{"kind":"relation","label":"co-mentioned with cancer center (11 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/62e1c129aef40faf3578189a"},{"kind":"relation","label":"co-mentioned with her2-mutant (11 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/51912d5dd1bf3704fb57f3ca"},{"kind":"relation","label":"co-mentioned with iiia (11 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/e03f49dec67d2ca3197aa5ca"},{"kind":"relation","label":"co-mentioned with t-dxd (11 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/dc4295128e8b95d077a0d7e5"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/16376562929e1bbae6b0e61a","mcp":"traverse {\"id\":\"sb:e/16376562929e1bbae6b0e61a\"}","page":"/entity/egfr-mutated/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/16376562929e1bbae6b0e61a\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/16376562929e1bbae6b0e61a\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/16376562929e1bbae6b0e61a\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/16376562929e1bbae6b0e61a\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}